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The major goal of this Concept Award project is to investigate whether a small molecule inhibitor of Bcl-xL will be able to overcome the chemo-and endocrine-resistance of breast cancer. Our hypothesis is that the anti-apoptotic molecule Bcl-xL may play certain role in apoptosis resistance as well as in acquired Tamoxifen resistance, and a small molecule Bcl-xL inhibitor might be able to block the development of this resistance and increase the effectiveness of chemo/hormone therapy.
Our basic hypothesis to be tested is that Bcl-xL is the primary molecular target that mediate the anticancer activity of the small molecule Bcl-xL inhibitor (-)-gossypol in human breast cancer cells. Our ultimate goal is to develop (-)-gossypol as a novel molecular targeted therapy for the treatment of breast cancer with Bcl-xL overexpression. In this project, we will investigate in vitro and in vivo anti-tumor activity and the mechanism of action of (-)-gossypol in human breast cancer with Bcl-xL overexpression, and investigate the potential synergistic effects of (-)-gossypol in combination with chemotherapy and hormone therapy.
II. Key research accomplishments:
This project is one-year Concept Award project. Due to the time required to finish the animal study, a 6-month no-cost extension was requested and approved. During the project period, we carried out the tasks proposed in the Statement of Work. Specifically, we carried out the following studied:
11.1.
To analyze the correlation of the expression levels of Bcl-xL and response to tamoxifen, to assess whether there is any link between Bcl-xL and antiestrogen response. In collaboration with University of Michigan Comprehensive Cancer Center Pathology and Immunohistology Core, we tried to perform immunohistochemistry (IHC) staining of tumor tissues to assess Bcl-xL expression. We have tested various Bcl-xL antibodies reportedly suitable for IHC from three vendors, the IHC staining we obtained were not distinctive enough to give us a convincing score for evaluation, although the histologists in the Core are well-trained and have many years' experience with IHC for breast cancer tissues. We are currently testing more antibodies, and using Bcl-xL-gene transfected tumor cell xenografts as positive control. However, within the funded Concept Award period, we did not obtain convincing IHC data to draw any conclusions.
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Using MCF-7 and T47D cells to investigate whether a Bcl-xl inhibitor can enhance the anti-tumor activity of chemo/hormone therapy.
II.2.1.(a)
Small molecule inhibitor of Bcl-xL Through structure-based design, we and others have discovered a natural product from cottonseed, gossypol, to be the most potent small molecule inhibitor of Bcl-xL(1, 2). The chemical structure of gossypol is shown in Chart I. Gossypol binds to the BH3 (Bcl-2 homology domain 3) binding pocket of Bcl-xL which is essential for its anti-apoptotic function. Gossypol induces apoptosis in cancer cells with a high level of Bcl-xL protein, but has minimal effect on cancer or normal cells with low Bcl-xL and low Bcl-2. Gossypol has two enantiomer forms, i.e., (-)-gossypol and (+)-gossypol. Previous studies on gossypol for its anticancer activity have been performed exclusively on (±)-gossypol. Our recent data suggest that (-)-gossypol is the active form mediating its anti-tumor art I. Chemicalbstr a potent Bcl-xL inhibitor activity. In this project, we focused on (-)-gossypol in our studies.
To provide a further insight on the structural basis of the 
II.2.1.(b) Gossypol mediated chemosensitization
To evaluate whether gossypol can enhance the anti-tumor activity of chemo/hormone therapy, we employed the Chou-Talalay combination index-isobologram and multiple drug dose-effect analysis method as described (3) . Briefly, in 96-well plates, 3000 -5000 cells/well human breast cancer cells were treated with (-)-gossypol and chemo/hormone therapeutic agents, alone or in combination. 4-6 days later, the cell survival was determined by WST-1 cell counting kit (Roche). The combination Index (CI) and Dose Reduction Index (DRI) for each combination dose ratio was calculated using the CalcuSyn software (www.biosoft.com). The optimal dose ratio in the drug combination that gives maximum synergy will be established based upon CI and DRI. Figure 5 . Gossypol enhances cytotoxicity of chemotherapeutic agents in MCF-7 the combination data cells. The lower two graphs are isobolograms corresponding to the WST assay data in both MCF-7 and above. (n=3)
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T47D cells. From Table 1 , we conclude that (-)-gossypol have better anti-tumor activity and more synergy than (+)-gossypol, in combination with chemotherapeutic agents, DOX, Taxol and gemcitabine (Gem). Gossypol showed minimal toxicity to MCF-1OA cells, the transformed human mammary epithelial cell line which has low levels of Bcl-xL (data not shown). 
II.2.1.(c) Gossypol in combination with hormone therapy
Similarly, we tested the combination activity of gossypol with Tamoxifen (Tam) and Feslodex (I0). MCF-7 and T47D cells were stripped with phenol red free IMEM, then plated in 96-well plates (3000 cell/well), treated with the drugs alone or in combination. 7-days later, the cell survival was determined by WST-1 cell counting kit (Roche). The combination Index (CI) and Dose Reduction Index (DRI) for each combination dose ratio was calculated as described above.
Using the optimal conditions for MCF-7 (E2 = 0.1nM, culture time 7 days, 3000 cell/well of MCF-7 cells) obtained from I1l.2. (Figure 2 ), we carried out cytotoxicity assays of gossypol in combination with anti- estrogen reagents, Tamoxifen (Tam), 4-hydroxy-Tamoxifen (4-Tam) or Feslodex (ICI). As shown in Figure  6A and 6B, the combination of gossypol with Tam or ICI did not shift the dose-response curves, indicating that no obvious drug-drug interactions were present with the conditions tested. We also tested 4-hydroxyTamoxifen, which is more potent than Tam in vitro. The combination of constant dose of gossypol with 4-Tam (Figure 6C ), or combining gossypol and 4-Tam in fixed ratios ( Figure 6B ), all showed additive activity. No significant synergy was observed in the conditions tested. Similar results were obtained in T47D cells. To investigate whether this observation is true for other Bcl-xL inhibitors, we also employed another small molecule Bcl-xL inhibitor, BL-106, which has a potent binding affinity to both Bcl-2 and Bcl-xL. Here again, we observed the similar results as with gossypol.
Taken together, with the experimental conditions tested so far, our data show that the small molecule Bcl-xL inhibitor gossypol can sensitize breast cancer cells to chemotherapy; however, no significant sensitization was observed with hormone therapy.
I1.2.2. Small interfering RNA (siRNA) against Bcl-xL
Small interfering RNA (siRNA) against Bcl-xL was established. We designed the siRNA based on BclxL mRNA and constructed psiBcl-xL, a vector-based siRNA, for establishing stable cancer cell clones with Bcl-xL knockdown. A siRNA specific to Firefly luciferase gene, psiLuc, was used as vector control.
II.2.2.(a) Transfection of MCF-7 cells with Bcl-xL siRNA vector, psiBcl-xL
MCF-7 cells were transfected with psiBcl-xL as we previously described(5). In some experiments, FuGene 6 (Roche) was used due to low toxicity and high efficiency for plasmid transfection. Briefly, 60% confluent cells were transfected with 1-3 ug psiBcl-xL or psiLuc DNA each well in a 6-well plate psiBcl-xL has green fluorescence protein (GFP) gene to monitor the transfection. MCF-7 cells transfected with psiBcl-xL showed significant cell death (up to 40%).
For stable clone selection, the MCF-7 cells were cultured in hygromycin selection media for two to three weeks and 4 clones with strong green fluorescence were picked. Figure 7 shows the fluorescent photos of MCF-7-psiBcl-xL stable clones. Note that the different MCF-7-psiBcl-xL clones have different levels of green fluorescence protein (GFP) expression. Theoretically, the level of GFP expression is proportional to the copy number of psiBcl-xL stably transfected in the cells, which is also corresponding to the level of Bcl-xL siRNA transcription from the plasmid psiBcl-xL. Indeed, as shown in Figure 8 , the Western blot analysis of MCF-7 psiBcl-xL stable clones, the MCF-7-psiBcl-xL clone #1 and #2 showed >95% and >90% down-regulation of Bcl-xL gene expression, respectively, whereas no significant effects on Bcl-xS and Bcl-2. Thus, the clones #1 and #2 have the strongest down-regulation of Bcl-xL, while these two clones also have the strongest green fluorescence. Interestingly, the clone #3 showed >60% down-regulation of Bcl-xL and has moderate green fluorescence, while the clone #4 showed no significant Bcl-xL-downregulation together with poor green fluorescence. Figure 8 . Western blot analysis of MCF-7 psiBcl-xL stable clones. psiBcl-xL clone #1 and #2 showed >95% and >90% down-regulation of Bcl-xL gene expression whereas no significant effects on Bcl-xS and Bcl-2. The clone #3 showed >60% down-regulation. Overexpression of anti-apoptotic protein Bcl-xL renders cancer cells more resistance to chemotherapeutic agents. Down-regulation of Bcl-xL by psiBcl-xL will overcome this apoptosis-resistance, thus enhance the induction of cell death by chemotherapy. As shown in Figure 8 , the MCF-7 psiBcl-xL Clone# 1 showed 5-fold more sensitive than psiLuc clone to docetaxel (TXT)-induced cell death ( Figure 8A ). The Clone#1 also showed a moderate sensitization to CDDP, although to a less extent ( Figure 8B ). The Clone#1 is the clone that has the best Bcl-xL gene knockdown (>95%, Figure 7 ).
Taken together, transfection of MCF-7 cells with psiBcl-xL resulted in up to 90% --95% downregulation of Bcl-xL protein. MCF-7 cells transfected with psiBcl-xL showed significant increase of cell death and/or apoptosis, slowed cell growth and increased sensitivity to chemotherapeutic agents. This tumor inhibitory activity of psiBcl-xL is related to the down-regulation of the intracellular level of Bcl-xL protein, by specific RNA-interference of Bcl-xL mRNA. pellets were put in. The tumorigenecity of MCF-7 clones treated with TXT these MCF-7 clones was summarized in Table 3 compensate for the down-regulated Bcl-xL "XT (pNO for protection. We are currently doing more studies to characterize these clones MCF-7 clones treated with CDDP for their molecular profiles, drug response, Values are tumor sizes (mm3).
I1.2.3. Pilot in vivo studies
II.2.3.(b)
Proof-of-concept pilot in vivo study in MCF-7 tumor regrowth model, to see whether Bcl-xl inhibitor can delay or even prevent the regrowth (relapse) of resistant tumor For MCF-7 tumor regrowth study, 10 x 107 cells were inoculated in mammary fat pad of ovariectomized female nude mice (Ncr-nu/nu), after E2 pellets (1.7 mg) were put in. 3-4 weeks later, when the tumors reach about 50 mm3 size, the E2 pellets were removed and Tamoxifen pellets (5 mg) were put in. Animal grouping: (a) positive control with new E2 pellet, (b) negative control with no E2 implant, (c) TAM only group with TAM pellet (5 mg) implant, (d) Gossypol only group, fed gossypol in drinking water, (e) Gossypol+TAM group with TAM implant, fed gossypol in drinking water. However, in the middle of experiment, the gossypol groups (Groups d and e) animals died in the second week of putting gossypol in drinking water, possibly due to toxicity. In pre-test for toxicity of gossypol, we have fed gossypol in drinking water to regular Balb/c mice for three weeks without significant toxicity, only minor body weight loss and the appearance of limited dehydration. It appears that the ovariectomized nude mice are more fragile and sensitive to gossypol. Further toxicity analysis is underway to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) in nude mice with gossypol fed in drinking water.
III. Reportable outcomes:
